For immediate release: May 12, 2008
Contact: Anne McMillin, APR
Office 775-682-9254
Mobile 702-292-4247
amcmillin@medicine.nevada.edu
School of Medicine pharmacology professor receives significant grant to study specific type of muscular dystrophy
National Institutes of Health grant awarded for $1,000,000 over five years
RENO, Nev.— Dean Burkin, Ph.D., an assistant professor of pharmacology at the University of Nevada School of Medicine and director of the Nevada Transgenic Center, has earned a substantial grant from the National Institutes of Health to study integrin-based therapies for muscular dystrophy.
The grant, awarded by the NIAMS (National Institute for Arthritis and Musculoskeletal and Skin Diseases) at the NIH, in the amount of $1,000,000, will continue over a five-year period that began May 1, 2008.
“Duchenne Muscular Dystrophy is an X-linked disease (on the X-chromosome) that affects one of 3,500 newborn boys,” said Burkin. “Around 45,000 children suffer from DMD in the United States and European Union.”
Children with this genetic disease are diagnosed at three-to-five years of age. They are confined to a wheelchair in their early teens, often on a respirator to help them breathe, and die in their 20s or 30s from cardiopulmonary failure. There is no effective treatment or cure for this genetic disease which is caused by mutations in a gene encoding a critical muscle protein called dystrophin. Loss of dystrophin in DMD patients leads to progressive muscle wasting.
“Using state-of-the-art transgenic mouse technology, we have previously demonstrated that increasing the levels of the alpha7beta1 integrin (a protein that appears to be functionally similar to dystrophin) can rescue mice with severe muscular dystrophy,” said Burkin.
The grant will investigate if increasing this integrin in muscle satellite cells (which are adult muscle stem cells required for muscle repair and are depleted in DMD patients) can more effectively promote muscle repair in mice with muscular dystrophy. In addition, Burkin will investigate if increasing this integrin in vascular smooth muscle can further alleviate muscle disease in these mice.
This latest grant follows on the heels of a two-year exploratory grant Burkin received from NINDS (National Institute of Neurological Disorders and Stroke) at the NIH last fall to investigate if there are drugs that can increase integrin expression in muscle cells. For this grant Burkin is screening libraries of drugs to identify compounds that may be used therapeutically for muscular dystrophy.
As the state’s only public medical school, the University of Nevada School of Medicine has been a leader in healthcare, medical education and research in Nevada since 1969. The School of Medicine includes 16 clinical departments including family medicine, pediatrics, obstetrics and gynecology, internal medicine, surgery, and psychiatry and behavioral sciences, and five nationally recognized departments in basic science including microbiology and biomedical engineering. The more than 185 doctors of University Health System, the school’s clinical practice, offer care in more than 40 medical specialties and subspecialties with eight physician offices in the Reno/Sparks area and seven in Las Vegas. The school is committed to a best practices approach to medicine and is dedicated to exceptional healthcare for Nevada now and in the future. For more information visit www.medicine.nevada.edu.